SWM
SRPT icon

SHP Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

SHP Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Buy
56
+21
+60% +$397 ﹤0.01% 1587
2026
Q1 		$762 Hold
35
– – ﹤0.01% 1530
2025
Q4 		$753 Buy
+35
New +$738 ﹤0.01% 1297

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SHP Wealth Management's SRPT Position: Q2 2026 in Review

SHP Wealth Management increased its Sarepta Therapeutics (SRPT) stake by 60% in Q2 2026, buying an estimated $397 and bringing the position to 56 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

SHP Wealth Management first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • SHP Wealth Management held 56 shares of Sarepta Therapeutics worth $1.01K as of Q2 2026.
  • SHP Wealth Management bought 21 Sarepta Therapeutics shares in Q2 2026, an estimated $397.
  • Sarepta Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1587 holding.
  • SHP Wealth Management first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.